Bayer reports solid Q2 revenues, Q2 sales rise 5.8%

Bayers’ revenues have mounted by 14.6% to €9.18 bl, largely due to growth in its consumer health and high-tech materials divisions. Net income has dropped to €525 mln, down from €532 mln a year earlier. Q2 net earnings fell by 1.3% owing to lawsuits and writing down a cancer drug. Bayer has taken special charges of €255 mnl in the quarter, of which €123 mln related to litigation and €132 mln from a partial write-down on cancer drug Zevalin.
  More News  Post Your Comment
{{comment.Name}} made a post.




There are no comments to display. Be the first one to comment!


Name Required.


Email Id Required.

Email Id Not Valid.


Mobile Required.

Email ID and Mobile Number are kept private and will not be shown publicly.

Message Required.

Click to Change image  Refresh Captcha